Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Jensen, Helle ^a   Andresen, Lars ^a   Nielsen, Jens ^b   Christensen, Jan Pravsgaard ^a   Skov, Søren ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN MICA; PROTEIN MICB; PROTEIN ULBP 2; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTINEOPLASTIC ANTIBIOTIC; ANTIVIRUS AGENT; DEPSIPEPTIDE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HLA ANTIGEN CLASS 1; KLRK1 PROTEIN, HUMAN; LIGAND; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; MICB ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; ROMIDEPSIN; SIGNAL PEPTIDE; ULBP2 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME REPRESSION; FLOW CYTOMETRY; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE EVASION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; VESICULAR STOMATITIS; VESICULAR STOMATITIS VIRUS; CELL MEMBRANE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VIROLOGY;

ADENOVIRIDAE; HUMAN HERPESVIRUS 5; VESICULAR STOMATITIS VIRUS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; DEPSIPEPTIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-ALPHA; JURKAT CELLS; LIGANDS; MUTATION; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VESICULAR STOMATITIS INDIANA VIRUS;

EID: 79961241823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023023     Document Type: Article

References (49)

1. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, et al. (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
2. Balachandran S, Porosnicu M, Barber GN, (2001) Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 75: 3474-3479.
3. Lichty BD, Power AT, Stojdl DF, Bell JC, (2004) Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 10: 210-216.
4. Clinton GM, Little SP, Hagen FS, Huang AS, (1978) The matrix (M) protein of vesicular stomatitis virus regulates transcription. Cell 15: 1455-1462.
5. Jayakar HR, Murti KG, Whitt MA, (2000) Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release. J Virol 74: 9818-9827.
6. Harty RN, Brown ME, McGettigan JP, Wang G, Jayakar HR, et al. (2001) Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J Virol 75: 10623-10629.
7. Her LS, Lund E, Dahlberg JE, (1997) Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus. Science 276: 1845-1848.
8. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
9. von KC, van Deursen JM, Rodrigues JP, Sitterlin D, Bachi A, et al. (2000) Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell 6: 1243-1252.
10. Faria PA, Chakraborty P, Levay A, Barber GN, Ezelle HJ, et al. (2005) VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell 17: 93-102.
11. Petersen JM, Her LS, Varvel V, Lund E, Dahlberg JE, (2000) The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol 20: 8590-8601.
12. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
13. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, et al. (2001) Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2: 255-260.
14. Groh V, Smythe K, Dai Z, Spies T, (2006) Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 7: 755-762.
15. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T, (2003) Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A 100: 9452-9457.
16. Vivier E, Tomasello E, Paul P, (2002) Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol 14: 306-311.
17. Routes JM, Ryan S, Morris K, Takaki R, Cerwenka A, et al. (2005) Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med 202: 1477-1482.
18. Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, et al. (2009) NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J Virol 83: 12345-12354.
19. Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, et al. (2003) Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med 197: 1427-1439.
20. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, et al. (2003) Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 33: 194-203.
21. Wu J, Chalupny NJ, Manley TJ, Riddell SR, Cosman D, et al. (2003) Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol 170: 4196-4200.
22. Zou Y, Bresnahan W, Taylor RT, Stastny P, (2005) Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol 174: 3098-3104.
23. McSharry BP, Burgert HG, Owen DP, Stanton RJ, Prod'homme V, et al. (2008) Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. J Virol 82: 4585-4594.
24. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, et al. (2005) Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65: 11136-11145.
25. Andresen L, Jensen H, Pedersen MT, Hansen KA, Skov S, (2007) Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells. J Immunol 179: 8235-8242.
26. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, et al. (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329.
27. Nguyen TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, et al. (2008) Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A 105: 14981-14986.
28. Nakhaei P, Mesplede T, Solis M, Sun Q, Zhao T, et al. (2009) The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation. PLoS Pathog 5: e1000650.
29. Enninga J, Levy DE, Blobel G, Fontoura BM, (2002) Role of nucleoporin induction in releasing an mRNA nuclear export block. Science 295: 1523-1525.
30. Connor JH, Lyles DS, (2002) Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. J Virol 76: 10177-10187.
31. Connor JH, Lyles DS, (2005) Inhibition of host and viral translation during vesicular stomatitis virus infection. eIF2 is responsible for the inhibition of viral but not host translation. J Biol Chem 280: 13512-13519.
32. Whitlow ZW, Connor JH, Lyles DS, (2006) Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome. J Virol 80: 11733-11742.
33. Thomas M, Boname JM, Field S, Nejentsev S, Salio M, et al. (2008) Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A 105: 1656-1661.
34. Chuang TH, Ulevitch RJ, (2004) Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol 5: 495-502.
35. Nachmani D, Lankry D, Wolf DG, Mandelboim O, (2010) The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat Immunol 11: 806-813.
36. Fernandez M, Porosnicu M, Markovic D, Barber GN, (2002) Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 76: 895-904.
37. Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, et al. (2009) Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58: 641-652.
38. Nuckel H, Switala M, Sellmann L, Horn PA, Durig J, et al. (2010) The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 24: 1152-1159.
39. Paschen A, Sucker A, Hill B, Moll I, Zapatka M, et al. (2009) Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15: 5208-5215.
40. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, et al. (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114: 560-568.
41. Groh V, Wu J, Yee C, Spies T, (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
42. Altomonte J, Wu L, Meseck M, Chen L, Ebert O, et al. (2009) Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther 16: 266-278.
43. Ireland DD, Reiss CS, (2006) Gene expression contributing to recruitment of circulating cells in response to vesicular stomatitis virus infection of the CNS. Viral Immunol 19: 536-545.
44. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, et al. (2003) Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198: 557-567.
45. Jensen H, Andresen L, Hansen KA, Skov S, (2009) Cell-surface expression of Hsp70 on hematopoietic cancer cells after inhibition of HDAC activity. J Leukoc Biol 86: 923-932.
46. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, et al. (2011) Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 30: 61-69.
47. Gasser S, Raulet DH, (2006) Activation and self-tolerance of natural killer cells. Immunol Rev 214: 130-142.
48. Fauriat C, Long EO, Ljunggren HG, Bryceson YT, (2010) Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 115: 2167-2176.
49. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH, (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171.